The final guidance confirms FDA’s enforcement discretion for many fitness and wellness technologies but raises issues for certain testing services.
On July 29, the US Food and Drug Administration (FDA) announced the availability of its guidance document, General Wellness: Policy for Low Risk Devices. This is the finalized version of the draft guidance document FDA issued on January 20, 2015. The final document describes FDA’s policy of enforcement discretion for devices that are intended for “general wellness” uses and are “low risk,” as those terms are defined in the final guidance. The finalization of this guidance document is a welcome step for the ever-expanding fitness/wellness technology industry, as it provides clarity and certainty that many such products, including wearable fitness trackers, weight loss apps, exercise equipment, and sleep management technologies, will be exempt from FDA oversight. However, changes made in the final version may adversely affect some consumer-oriented testing services and products that require blood samples.
The final guidance exempts from active FDA oversight devices that are intended only for general wellness use and present a low risk to the safety of users and other persons. With regard to the first factor, FDA states that a general wellness product includes those that are intended to (1) maintain or encourage a general state of health or a healthy activity or (2) support a healthy lifestyle to reduce the risk or impact of certain chronic diseases or conditions. The final guidance states that the second type of general wellness claim may only be used “where it is well understood and accepted that healthy lifestyle choices may play an important role in health outcomes for the disease or condition.”
In determining whether a product is low risk, FDA identifies three factors to consider:
If the answer to any of the above questions is “yes,” the product does not qualify as low risk.
Overall, the final guidance is very similar to the draft guidance. Although most changes made from the draft version were minor or stylistic, some were more significant, including the following:
Of the new examples added to the guidance, one in particular may affect the fast-growing market for consumer-oriented testing services—FDA states in Section IV that a product intended to enhance athletic performance by providing suggestions based on lactic acid testing would not be considered low risk if it “uses venipuncture to obtain the blood samples needed for testing.” This example suggests that certain testing products or services that require blood samples using venipuncture would not qualify as low risk under the final guidance and would not be subject to enforcement discretion. It also signals that FDA considers tests for athletic performance to be medical devices.
If you have any questions about the issues discussed in this LawFlash, please contact any of the following Morgan Lewis lawyers:
Michele L. Buenafe